Meeder Asset Management Inc Bluebird Bio, Inc. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$8.96 - $16.31 $143 - $260	-16 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$11.24 - $21.0 $134 - $252	-12 Reduced 42.86%	16 $0
Q3 2020 Nov 02, 2020	SELL	$34.44 - $43.75 $1,205 - $1,531	-35 Reduced 55.56%	28 $2,000
Q2 2020 Aug 11, 2020	SELL	$27.12 - $45.97 $2,820 - $4,780	-104 Reduced 62.28%	63 $4,000
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $2,511 - $6,096	96 Added 135.21%	167 $8,000
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $234 - $308	5 Added 7.58%	71 $6,000
Q3 2019 Oct 17, 2019	BUY	$59.47 - $93.1 $1,546 - $2,420	26 Added 65.0%	66 $6,000
Q2 2019 Aug 05, 2019	BUY	$75.84 - $105.21 $3,033 - $4,208	40 New	40 $5,000
Q3 2018 Nov 02, 2018	SELL	$88.86 - $117.49 $18,571 - $24,555	-209 Closed	0 $0
Q2 2018 Jul 24, 2018	SELL	$99.64 - $127.59 $31,386 - $40,190	-315 Reduced 60.11%	209 $0
Q1 2018 May 03, 2018	SELL	$105.8 - $150.94 $12,378 - $17,659	-117 Reduced 18.25%	524 $89,000
Q4 2017 Feb 02, 2018	BUY	$81.25 - $130.7 $49,725 - $79,988	612 Added 2110.34%	641 $114,000
Q3 2017 Oct 20, 2017	BUY	$57.74 - $91.42 $1,674 - $2,651	29	29 $4,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.